Rock Springs Capital ALT Position
Exited3-Fund ConvergenceRock Springs Capital exited their position in Altimmune, Inc. (ALT) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
ALT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Pemvidutide in 45 days (May 31, 2026), making the timing of Rock Springs's position particularly relevant.
Rock Springs Capital ALT Position History
Frequently Asked Questions
Does Rock Springs Capital own ALT?
No. Rock Springs Capital exited their position in Altimmune, Inc. (ALT) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own ALT?
3 specialist biotech hedge funds currently hold ALT, including Tang Capital Management, Boxer Capital, OrbiMed Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy ALT?
Rock Springs Capital's position in ALT was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's ALT position increasing or decreasing?
Rock Springs Capital completely exited their ALT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →